Información del artículo
El Texto completo está disponible en PDF
Bibliografía
[1.]
D. Resnick, G. Niwayama.
Ankylosing spondylitis.
Diagnosis of bone and joint disorders, 3rd ed., pp. 1008-1074
[2.]
W.W. Ginsburg, M.D. Cohen.
Peripheral arthritis in ankylosing spondylitis. A review of 209 patients followed for more than 20 years.
Mayo Clin Proc, 58 (1983), pp. 593-596
[3.]
M. Wilkinson, E.G.L. Bywaters.
Clinical features and course of ankylosing spondylitis; as seen in a follow-up of 222 hospital referred cases.
Ann Rheum Dis, 17 (1958), pp. 209-228
[4.]
S. Carette, D.C. Graham, H. Little, et al.
The natural disease course of ankylosing spondylitis.
Arthritis Rheum, 26 (1983), pp. 186-190
[5.]
J. Brant, H. Haibel, D. Cornely, et al.
Successful treatment of active ankylosing spondylitis with the anti-tumour necrosis factor alfa monoclonal antibody infliximab.
Arthritis Rheum, 43 (2000), pp. 1346-1352
[6.]
W.P. Maksymowych, G.S. Jhangri, R.G. Lambert, C. Mallon, H. Buenviaje, E. Pedrycz, et al.
Infliximab in ankylosing spondylitis: A prospective observational inception cohort analysis of efficacy and safety.
J Rheumatol, 29 (2002), pp. 959-965
[7.]
J. Braun, J. Brandt, J. Listing, A. Zink, R. Alten, W. Golder, et al.
Treatment of active ankylosing spondylitis with infliximab: a randomized controlled multicenter trial.
Lancet, 359 (2002), pp. 1187-1193
[8.]
J. Braun, X. Baraliakos, W. Golder, J. Listing, J. Brandt, M. Bollow, et al.
Improvement in spinal inflammation in ankylosing spondylitis by infliximab therapy as assessed by a magnetic resonance imaging using a novel evaluated spinal scoring system-results of a double-blind placebo-controlled trial [abstract].
Arthritis Rheum, 46 (2002), pp. S426
Copyright © 2005. Elsevier España S.L. Barcelona
